Condition: Efficacy and Safety · Sponsor: University of Liege
The main objective is to assess the efficacy of local injection of MSC on the healing of refractory intestinal and perianal lesions in crohn disease. The second co-primary endpoint is safety.
This description comes directly from the study's public registry record.
Edouard Louis, Prof · 043667256 · edouard.louis@uliege.be
Chantal Lechanteur · 043668390 · c.lechanteur@chuliege.be
Always discuss trial participation with your own doctor first.
| CHU de Liège | Liège, Liège, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03901235